Search Results - "Cha, Bong‐Soo"

Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008‐2011) by Lee, Yong‐ho, Kim, Seung Up, Song, Kijun, Park, Jun Yong, Kim, Do Young, Ahn, Sang Hoon, Lee, Byung‐Wan, Kang, Eun Seok, Cha, Bong‐Soo, Han, Kwang‐Hyub

“…Sarcopenia is associated with nonalcoholic fatty liver disease (NAFLD). This study investigated whether sarcopenia is associated with significant liver…”
Get full text

SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease by Kim, So Ra, Lee, Sang-Guk, Kim, Soo Hyun, Kim, Jin Hee, Choi, Eunhye, Cho, Wonhee, Rim, John Hoon, Hwang, Inhwa, Lee, Chan Joo, Lee, Minyoung, Oh, Chang-Myung, Jeon, Justin Y., Gee, Heon Yung, Kim, Jeong-Ho, Lee, Byung-Wan, Kang, Eun Seok, Cha, Bong-Soo, Lee, Myung-Shik, Yu, Je-Wook, Cho, Jin Won, Kim, Jung-Sun, Lee, Yong-ho

“…Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce cardiovascular events in humans with type 2 diabetes (T2D); however, the underlying mechanism remains…”
Get full text

Nonalcoholic Fatty Liver Disease and Sarcopenia Are Independently Associated With Cardiovascular Risk by Han, Eugene, Lee, Yong-ho, Kim, Young Dae, Kim, Beom Kyung, Park, Jun Yong, Kim, Do Young, Ahn, Sang Hoon, Lee, Byung-Wan, Kang, Eun Seok, Cha, Bong-Soo, Han, Kwang-Hyub, Nam, Hyo Suk, Heo, Ji Hoe, Kim, Seung Up

“…Nonalcoholic fatty liver disease (NAFLD) and sarcopenia have a close association with an increased risk of atherosclerotic cardiovascular disease (ASCVD). This…”
Get full text

Ezetimibe ameliorates steatohepatitis via AMP activated protein kinase-TFEB-mediated activation of autophagy and NLRP3 inflammasome inhibition by Kim, Soo Hyun, Kim, Gyuri, Han, Dai Hoon, Lee, Milim, Kim, Irene, Kim, Bohkyung, Kim, Kook Hwan, Song, Young-Mi, Yoo, Jeong Eun, Wang, Hye Jin, Bae, Soo Han, Lee, Yong-Ho, Lee, Byung-Wan, Kang, Eun Seok, Cha, Bong-Soo, Lee, Myung-Shik

“…Impairment in macroautophagy/autophagy flux and inflammasome activation are common characteristics of nonalcoholic steatohepatitis (NASH). Considering the lack…”
Get full text

Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study) by Cho, Yongin, Rhee, Hyungjin, Kim, Young-Eun, Lee, Minyoung, Lee, Byung-Wan, Kang, Eun Seok, Cha, Bong-Soo, Choi, Jin-Young, Lee, Yong-Ho

“…The effect of ezetimibe, Niemann-Pick C1-like 1 inhibitor, on liver fat is not clearly elucidated. Our primary objective was to evaluate the efficacy of…”
Get full text

Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study by Han, Eugene, Lee, Byung-Wan, Kang, Eun Seok, Cha, Bong-Soo, Ahn, Sang Hoon, Lee, Yong-ho, Kim, Seung Up

“…A new fatty liver disease nomenclature, steatotic liver disease (SLD) has been proposed; however, there are no data on clinical outcomes. We investigated the…”
Get full text

Sodium‐glucose cotransporter 2 inhibitors regulate ketone body metabolism via inter‐organ crosstalk by Kim, Jin Hee, Lee, Minyoung, Kim, Soo Hyun, Kim, So Ra, Lee, Byung‐Wan, Kang, Eun Seok, Cha, Bong‐Soo, Cho, Jin Won, Lee, Yong‐ho

“…Aim To investigate sodium‐glucose cotransporter 2 inhibitor (SGLT2i)‐induced changes in ketogenic enzymes and transporters in normal and diabetic mice models…”
Get full text

Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis by Lee, Yong Ho, Cho, Yongin, Lee, Byung Wan, Park, Cheol Young, Lee, Dae Ho, Cha, Bong Soo, Rhee, Eun Jung

“…Nonalcoholic fatty liver disease (NAFLD) and diabetes are common metabolic disorders whose prevalence rates are expected to rise worldwide, corresponding to…”
Get full text

MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study by Han, Eugene, Chun, Ho Soo, Lee, Yong-Ho, Lee, Jae Seung, Lee, Hye Won, Kim, Beom Kyung, Park, Jun Yong, Kim, Do Young, Lee, Byung-Wan, Kang, Eun Seok, Cha, Bong-Soo, Ahn, Sang Hoon, Kim, Seung Up

“…Clinical features of non-alcoholic fatty liver disease (NAFLD), but not fulfilling the diagnostic criteria of metabolic dysfunction-associated fatty liver…”
Get full text

Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease by Kim, Yuna, Han, Eugene, Lee, Jae Seung, Lee, Hye Won, Kim, Beom Kyung, Kim, Mi Kyung, Kim, Hye Soon, Park, Jun Yong, Kim, Do Young, Ahn, Sang Hoon, Lee, Byung-Wan, Kang, Eun Seok, Cha, Bong-Soo, Lee, Yong-Ho, Kim, Seung Up

“…: Nonalcoholic fatty liver disease (NAFLD) and obesity are independently associated with an increased risk for atherosclerotic cardiovascular disease (ASCVD),…”
Get full text

Nonalcoholic fatty liver disease, diastolic dysfunction, and impaired myocardial glucose uptake in patients with type 2 diabetes by Lee, Minyoung, Kim, Kwang Joon, Chung, Tae‐Ha, Bae, Jaehyun, Lee, Yong‐ho, Lee, Byung‐Wan, Cha, Bong‐Soo, Yun, Mijin, Kang, Eun Seok

“…Aims To investigate whether degree of nonalcoholic fatty liver disease (NAFLD) is associated with myocardial dysfunction related to impaired myocardial glucose…”
Get full text

Risk of Incident Dementia According to Metabolic Health and Obesity Status in Late Life: A Population-Based Cohort Study by Lee, Ji-Yeon, Han, Kyungdo, Han, Eugene, Kim, Gyuri, Cho, Hanna, Kim, Kwang Joon, Lee, Byung Wan, Kang, Eun Seok, Cha, Bong-Soo, Brayne, Carol, Lee, Yong-ho

“…Abstract Context The risk for dementia among subjects who are obese with normal metabolic profiles, or called metabolically healthy obese (MHO), remains…”
Get full text

Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo‐controlled, double‐blind, multicenter trial by Lu, Chieh‐Hsiang, Min, Kyung Wan, Chuang, Lee‐Ming, Kokubo, Satoshi, Yoshida, Satoshi, Cha, Bong‐Soo

“…Aims/Introduction To determine the efficacy and safety of ipragliflozin in combination with metformin in Asian patients with type 2 diabetes mellitus…”
Get full text

Efficacy and safety of ipragliflozin as an add‐on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial by Han, Kyung‐Ah, Chon, Suk, Chung, Choon Hee, Lim, Soo, Lee, Kwan‐Woo, Baik, SeiHyun, Jung, Chang Hee, Kim, Dong‐Sun, Park, Kyong Soo, Yoon, Kun‐Ho, Lee, In‐Kyu, Cha, Bong‐Soo, Sakatani, Taishi, Park, Sumi, Lee, Moon‐Kyu

“…Aim To evaluate the efficacy and safety of ipragliflozin vs placebo as add‐on therapy to metformin and sitagliptin in Korean patients with type 2 diabetes…”
Get full text

Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus by Bae, Jaehyun, Park, Taegyun, Kim, Hyeyoung, Lee, Minyoung, Cha, Bong-Soo

“…Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance and β-cell dysfunction. Among available oral antidiabetic agents, only the…”
Get full text

The effects of the voglibose on non-alcoholic fatty liver disease in mice model by Bae, Jaehyun, Lee, Ji Young, Shin, Eugene, Lee, Minyoung, Lee, Yong-ho, Lee, Byung-Wan, Kang, Eun Seok, Cha, Bong-Soo

“…The α-glucosidase inhibitor (α-GI) delays the intestinal absorption of glucose, which reduces postprandial hepatic glucose intake. This mechanism is considered…”
Get full text

Association between betatrophin/ANGPTL8 and non-alcoholic fatty liver disease: animal and human studies by Lee, Yong-ho, Lee, Sang-Guk, Lee, Chan Joo, Kim, Soo Hyun, Song, Young-Mi, Yoon, Mi Ra, Jeon, Byung Hun, Lee, Jae Hyuk, Lee, Byung-Wan, Kang, Eun Seok, Lee, Hyun Chul, Cha, Bong-Soo

“…Betatrophin/angiopoietin-like protein 8 (ANGPTL8) is a liver-secreted protein recently identified as a potent stimulator of beta cell proliferation in mice…”
Get full text

Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial by Han, Eugene, Lee, Yong-Ho, Lee, Byung-Wan, Kang, Eun Seok, Cha, Bong-Soo

“…Despite the benefits of pioglitazone in the treatment of non-alcoholic fatty liver disease (NAFLD), many treated patients continue to experience disease…”
Get full text

Metformin Restores Parkin-Mediated Mitophagy, Suppressed by Cytosolic p53 by Song, Young Mi, Lee, Woo Kyung, Lee, Yong-Ho, Kang, Eun Seok, Cha, Bong-Soo, Lee, Byung-Wan

“…Metformin is known to alleviate hepatosteatosis by inducing 5' adenosine monophosphate (AMP)-kinase-independent, sirtuin 1 (SIRT1)-mediated autophagy…”
Get full text

Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease by Han, Eugene, Lee, Yong-Ho, Lee, Jae Seung, Lee, Hye Won, Kim, Beom Kyung, Park, Jun Yong, Kim, Do Young, Ahn, Sang Hoon, Lee, Byung-Wan, Kang, Eun Seok, Cha, Bong-Soo, Kim, Seung Up

“…Metabolic dysfunction associated fatty liver disease (MAFLD) has recently been introduced to compensate for the conventional concept of nonalcoholic fatty…”
Get full text